NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Research these facts:

Dr. Liau is backed by FDA-NIH. DCVax would not exist without the NIH funding that led to its development. NIH is today funding the DCVax doses going into patients’ arms in the Keytruda study. FDA-NIH has been backing Dr. Liau for years.

Dr. Ashkan is the chief of the clinical trials unit at Kiing’s College and Dr. Ashkan is an advisor to the U.K. government. MHRA has already demonstrated its support for the development of the DCVax platform technology and that support has only strengthened in recent months. MHRA values Dr. Ashkan’s work and supports DCVax.

https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter

https://newsroom.ucla.edu/releases/nih-grant-lab-gene-cell-therapies

https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/

https://www.bentley.edu/news/nih-funded-research-related-every-new-cancer-drug-approved-2010-2016

https://www.uclahealth.org/providers/linda-liau

https://www.kcl.ac.uk/people/keyoumars-ashkan

https://virtualtrials.org/dcvax.cfm